Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of treatment: an antibody designed to wipe out cancerous B cells plus a ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

A pair of newly developed models may help better predict outcomes in patients with diffuse large B-cell lymphoma (DLBCL). The ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...

– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...

How Can Biomarkers Help Individualize Treatment of Diffuse Large B-cell Lymphoma? Using Biomarkers to Diagnose Diffuse Large B-cell Lymphoma ...

ctDNA testing could help doctors track response, reduce unnecessary chemo, and identify relapse early for patients with aggressive B cell lymphomas. Dr. Hua-Jay Cherng, a hematologist oncologist at ...

Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive a less toxic treatment than the intensive chemotherapy often used, according to new research from Sylvester ...

Many people with an aggressive blood cancer called diffuse large B cell lymphoma are cured by the current gold standard of ...

Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...